Innate Pharma IPHA
NASDAQ IPHA
$1.57 -0.01 (-0.51%)
As of: Oct 21, 2026 · 10:23 AM EDT

Innate Pharma (IPHA) Long-Term Debt Repayments (2019)

Updated

Innate Pharma (IPHA) reported Long-Term Debt Repayments of -$10.37 million for the quarter ended Dec 31, 2025, compared with -$9.55 million a year earlier.

Analysis

Innate Pharma (IPHA) Long-Term Debt Repayments (2019) Analysis & Trends

For the year ended Dec 31, 2025, Innate Pharma posted Long-Term Debt Repayments of -$10.07 million.

  • By year, Long-Term Debt Repayments came in at -$9.67 million in the year ended Dec 31, 2024, -$2.55 million in the year ended Dec 31, 2023, -$2.14 million in the year ended Dec 31, 2022 and -$2.37 million in the year ended Dec 31, 2021.
  • The figure for the quarter ended Dec 31, 2025 ranks as the lowest quarterly Long-Term Debt Repayments in data going back to the quarter ended Jun 30, 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.80 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 614.95 Bn 533.47 Bn 17.26 Bn 1.00 Mn
3 AbbVie 505.05 Bn 478.16 Bn 12.70 Bn 2.00 Bn
4 Merck 368.08 Bn 322.46 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 298.32 Bn 262.31 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 261.58 Bn 235.26 Bn 12.86 Bn 2.46 Bn
7 Amgen 236.05 Bn 191.45 Bn 7.24 Bn -
8 Gilead Sciences 190.61 Bn 164.80 Bn 6.22 Bn 17.00 Mn
9 Pfizer 169.86 Bn 116.50 Bn 10.94 Bn -
10 Innate Pharma 140.66 Mn -66.54 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 -819,132.90
API Access

Innate Pharma Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=IPHA&period=max&api_key=YOUR_API_KEY